Sertraline
- Generic Name
- Sertraline
- Brand Names
- Zoloft
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17Cl2N
- CAS Number
- 79617-96-2
- Unique Ingredient Identifier
- QUC7NX6WMB
- Background
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
...
- Indication
Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety di...
- Associated Conditions
- Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
- Associated Therapies
- -
Treatments for Depression: Drug Versus Psychotherapy
- Conditions
- Interventions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 156
- Registration Number
- NCT00043550
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Depression and Health Outcomes in Refractory Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2001-11-15
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 140
- Registration Number
- NCT00026637
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
- Conditions
- First Posted Date
- 2001-07-23
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 4000
- Registration Number
- NCT00021528
- Locations
- 🇺🇸
Harbor UCLA Family Health Care Center, Harbor City, California, United States
🇺🇸UCLA General Outpatient Psychiatry Clinic, Los Angeles, California, United States
🇺🇸UCLA Internal Medicine Clinic, Los Angeles, California, United States
Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9
- Conditions
- First Posted Date
- 2001-04-18
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00015132
- Locations
- 🇺🇸
Cincinnati MDRU, Cincinnati, Ohio, United States
Treatment of Major Depression With St. John's Wort (Hypericum)
- Conditions
- First Posted Date
- 2000-04-03
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Registration Number
- NCT00005013
- Locations
- 🇺🇸
Univ of Cincinnati Medical Ctr, Cincinnati, Ohio, United States
🇺🇸Univ of Texas Southwestern Med Ctr, Dallas, Texas, United States
🇺🇸Seattle Clinical Research Center, Seattle, Washington, United States
Treatment of Obsessive-Compulsive Disorder (OCD) in Children
- Conditions
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- University of Pennsylvania
- Registration Number
- NCT00000384
- Locations
- 🇺🇸
Duke Univ. Med. Ctr., Durham, North Carolina, United States
🇺🇸Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Yale University
- Target Recruit Count
- 198
- Registration Number
- NCT00000451
Antidepressant Treatment of Melancholia in Late Life
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 110
- Registration Number
- NCT00000378
- Locations
- 🇺🇸
1051 Riverside Drive, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.